[
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Shares React as FDA Grants Multiple Designations to Nipocalimab",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were significant events during the quarter. Additionally, the company's ongoing regulatory strides, including new designations for nipocalimab, offered a robust pipeline outlook. However, despite a 5% stock increase in the last quarter, JNJ's performance remained largely aligned with market...",
    "url": "https://finnhub.io/api/news?id=d99df35d1c1095d4f157397e48a80b3da1f0861c50bc77923653aa8260ca723c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744222188,
      "headline": "Johnson & Johnson (NYSE:JNJ) Shares React as FDA Grants Multiple Designations to Nipocalimab",
      "id": 133841357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were significant events during the quarter. Additionally, the company's ongoing regulatory strides, including new designations for nipocalimab, offered a robust pipeline outlook. However, despite a 5% stock increase in the last quarter, JNJ's performance remained largely aligned with market...",
      "url": "https://finnhub.io/api/news?id=d99df35d1c1095d4f157397e48a80b3da1f0861c50bc77923653aa8260ca723c"
    }
  },
  {
    "ts": null,
    "headline": "Trump says pharmaceutical tariffs may be coming: What to know",
    "summary": "Drugmaker stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that he may impose tariffs on pharmaceutical imports. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=a04ba988dddb39f80fffc7912b11ca46a589bf0f30c8ab29645f4be12e91d0bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744207917,
      "headline": "Trump says pharmaceutical tariffs may be coming: What to know",
      "id": 133828249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Drugmaker stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that he may impose tariffs on pharmaceutical imports. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=a04ba988dddb39f80fffc7912b11ca46a589bf0f30c8ab29645f4be12e91d0bb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
    "summary": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer all fell at least 2% Wednesday morning.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK also fell 2% or more in the U.S.",
    "url": "https://finnhub.io/api/news?id=4ad9c1d7fea3deeec7d2b3a280135f38198b941591a33ba2179d1043ce0de99c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744206677,
      "headline": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
      "id": 133828256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer all fell at least 2% Wednesday morning.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK also fell 2% or more in the U.S.",
      "url": "https://finnhub.io/api/news?id=4ad9c1d7fea3deeec7d2b3a280135f38198b941591a33ba2179d1043ce0de99c"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Upgrades Johnson & Johnson (JNJ)",
    "summary": "Goldman Sachs Upgrades Johnson & Johnson (JNJ)",
    "url": "https://finnhub.io/api/news?id=7117b90dd0fb3487881bf2948e28a1e142f83e8b8542dc4f1e32cc1f901d011a",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744200267,
      "headline": "Goldman Sachs Upgrades Johnson & Johnson (JNJ)",
      "id": 133827439,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7117b90dd0fb3487881bf2948e28a1e142f83e8b8542dc4f1e32cc1f901d011a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson, Amgen share losses contribute to Dow's 100-point drop",
    "summary": "Johnson & Johnson, Amgen share losses contribute to Dow's 100-point drop",
    "url": "https://finnhub.io/api/news?id=e27971560febbb982a6ff26dac51197f646ae4bbe9a6cd38a00460b2d2d4f9ed",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744199820,
      "headline": "Johnson & Johnson, Amgen share losses contribute to Dow's 100-point drop",
      "id": 133836304,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson, Amgen share losses contribute to Dow's 100-point drop",
      "url": "https://finnhub.io/api/news?id=e27971560febbb982a6ff26dac51197f646ae4bbe9a6cd38a00460b2d2d4f9ed"
    }
  },
  {
    "ts": null,
    "headline": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
    "summary": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
    "url": "https://finnhub.io/api/news?id=239fef194b45c3e0deed88ea159536c67bcfdddecfa594d190ef5f32a420718c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744199340,
      "headline": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
      "id": 133844748,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
      "url": "https://finnhub.io/api/news?id=239fef194b45c3e0deed88ea159536c67bcfdddecfa594d190ef5f32a420718c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis",
    "summary": "SPRING HOUSE - Johnson & Johnson today announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label extensiona , evaluating the long-term...",
    "url": "https://finnhub.io/api/news?id=be184935413a9bf758ead370d7e954175f0e25e79e579bd2d112b79b2cbf3eaa",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744198426,
      "headline": "Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis",
      "id": 133833078,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "SPRING HOUSE - Johnson & Johnson today announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label extensiona , evaluating the long-term...",
      "url": "https://finnhub.io/api/news?id=be184935413a9bf758ead370d7e954175f0e25e79e579bd2d112b79b2cbf3eaa"
    }
  },
  {
    "ts": null,
    "headline": "Amgen, Merck share losses contribute to Dow's 262-point drop",
    "summary": "Amgen, Merck share losses contribute to Dow's 262-point drop",
    "url": "https://finnhub.io/api/news?id=6060dbf8ddfa610787306cff9b36ca17e9e02761f5949a9e6d1e8f42f1a42faa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744196160,
      "headline": "Amgen, Merck share losses contribute to Dow's 262-point drop",
      "id": 133830570,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Amgen, Merck share losses contribute to Dow's 262-point drop",
      "url": "https://finnhub.io/api/news?id=6060dbf8ddfa610787306cff9b36ca17e9e02761f5949a9e6d1e8f42f1a42faa"
    }
  },
  {
    "ts": null,
    "headline": "Mar Vista U.S. Quality Premier Strategy Q1 2025 Commentary",
    "summary": "Mar Vista U.S. Quality Premier Strategy Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=5d1db2072218b3c756c5f54e504f1e2464d1f3287819271d6c4ab907ca089d76",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744195500,
      "headline": "Mar Vista U.S. Quality Premier Strategy Q1 2025 Commentary",
      "id": 133830644,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5d1db2072218b3c756c5f54e504f1e2464d1f3287819271d6c4ab907ca089d76"
    }
  },
  {
    "ts": null,
    "headline": "Mar Vista U.S. Quality Q1 2025 Commentary",
    "summary": "Mar Vista U.S. Quality Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=b402e3eb56d62b2c08f6e8b6787df9601c844b1dc0d698ca3b0f64f247e58a17",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744192800,
      "headline": "Mar Vista U.S. Quality Q1 2025 Commentary",
      "id": 133828022,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b402e3eb56d62b2c08f6e8b6787df9601c844b1dc0d698ca3b0f64f247e58a17"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Goldman Sachs share losses lead Dow's 166-point fall",
    "summary": "Merck, Goldman Sachs share losses lead Dow's 166-point fall",
    "url": "https://finnhub.io/api/news?id=fedda70006cdbcdf41609b628db08d5e1884d8ff447d818ede58e89d4cfcce97",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744192020,
      "headline": "Merck, Goldman Sachs share losses lead Dow's 166-point fall",
      "id": 133829335,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Merck, Goldman Sachs share losses lead Dow's 166-point fall",
      "url": "https://finnhub.io/api/news?id=fedda70006cdbcdf41609b628db08d5e1884d8ff447d818ede58e89d4cfcce97"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Strategy Q1 2025 Commentary",
    "summary": "ClearBridge Value Strategy Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=35535e3cea80b09456684a0cb073c03b1717d2f8f368e5df3aa2bd24396ed4a2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744182000,
      "headline": "ClearBridge Value Strategy Q1 2025 Commentary",
      "id": 133826903,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=35535e3cea80b09456684a0cb073c03b1717d2f8f368e5df3aa2bd24396ed4a2"
    }
  }
]